Kite Pharma is a biotech company developing a pipeline of product candidates using its therapeutic platform: engineered Autologous Cell Therapy (eACT).
Kite Pharma – engineered Autologous Cell Therapy
Kite Pharma is developing a pipeline of proprietary eACT-based product candidates to create personalized therapies targeting a broad range of cancers. In this innovative technology, a patient’s peripheral blood T cells are genetically modified ex vivo to express receptor molecules that render these T cells highly efficacious against cancer. This engineered Autologous Cell Therapy technology involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs), or T cell receptors (TCRs). Both categories of products encompass extracellular tumor antigen recognition domains and endogenous or engineered intracellular T cell activating domains, ensuring a broad coverage across intracellular and membrane targets, solid tumors and hematological malignancies. Clinical studies of engineered T cells have shown significant and durable objective clinical responses in cancer patients with advanced metastatic disease (lymphoma, leukemia, refractory melanoma, sarcoma, etc…). Additionally, Kite Pharma is developing a diversified pipeline of CAR and TCR products with broad applicability across various tumor types: Granulocyte monocyte colony stimulating factor (GM-CSF: a cytokine critical for immune activation), and CAIX (a hypoxia-induced protein known to contribute to tumor cell survival and cancer progression).
The eACT platform is the foundation for Kite Pharma’s lead programs in collaboration with the National Cancer Institute (NCI), which is advancing multiple clinical trials in patients with hematological and solid tumors. Kite Pharma has a Cooperative Research and Development Agreement (CRADA) with the NCI and holds the right to exclusive commercialization licenses from the National Institute of Health (NIH) related to the CRADA research plans.
More about Kite Pharma : www.kitepharma.com